3 ASX 200 healthcare stocks with 'strong return potential' in 2025

A leading investment manager expects 2025 will be a good year for these ASX 200 healthcare companies.

| More on:
Happy healthcare workers in a labs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to benefit from growing demand for their services in 2025.

That's according to Piers Bolger, chief investment officer of Infinity Asset Management.

Commenting on the investment outlook for 2025, Bolger said, "Overall, the investment outlook for 2025 is positive but cautious."

He added:

Lower interest rates and strong equity dynamics present opportunities but risks like geopolitical tensions and uneven global growth require careful navigation. A flexible, growth-focused approach will be essential to manage challenges and seize opportunities.

Citing high valuations and declining earnings, Bolger said he's cautious on ASX 200 bank stocks.

But he has a positive outlook for the healthcare sector.

ASX 200 healthcare stocks facing demand growth in 2025

Drilling into three specific ASX 200 healthcare stocks he's bullish on, Bolger named global pathology provider Sonic Healthcare Ltd (ASX: SHL), biotech giant CSL Ltd (ASX: CSL), and sleep disorder treatment company ResMed Inc (ASX: RMD).

"Companies like CSL, ResMed, and Sonic Healthcare are set to benefit from growing demand for pathology, blood plasma, and medical devices," he said. "These companies are trading at attractive prices and have strong return potential."

What's been happening with the Aussie healthcare companies?

ResMed reported its first quarter FY 2025 results on 25 October.

The ASX 200 healthcare stock gained 5.9% on the day after reporting an 11% year on year lift in revenue for the three months to 30 September of US$1.22 billion. 34% Operating profit was up 34% from the prior corresponding quarter.

Increased demand for the company's sleep devices and masks drove revenue growth. ResMed also reported growth across its Residential Care Software segment.

"Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business," ResMed CEO Mick Farrell said at the time.

ASX 200 healthcare stock Sonic reported its full FY 2024 results on 22 August.

Core financial metrics included a 9.8% year-on-year increase in revenue to $8.97 billion. Net profit after tax (NPAT) was down 25% from FY 2023 to $511 million.

"The 2024 financial year can be summarised as a transition period for Sonic Healthcare, as we moved away from the impacts of the pandemic towards business as usual," Sonic CEO Colin Goldschmidt said at the time.

As for CSL, the biotech company reported its FY 2024 results on 13 August.

The ASX 200 healthcare stock achieved an 11% year-on-year increase in revenue (in constant currency) to US$14.8 billion. And net profit after tax before amortisation was up 11% to US$2.91 billion.

"Our largest franchise, the immunoglobulins portfolio, delivered exceptional growth driven by significant patient demand, and the recovery in CSL Behring's gross margin is progressing to plan," CSL CEO Paul McKenzie said following the results.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »